Alnylam (ALNY) Q3 2024: TTR Franchise Climbs 34% as ATTR-CM Launch Preparation Accelerates

October 31, 2024 | By EarningsIQ Research

Alnylam delivered robust 34% growth in its TTR franchise, positioning Ambutra for a pivotal ATTR cardiomyopathy launch in 2025. The company advanced its CNS pipeline with early Alzheimer’s data and continued disciplined resource allocation, while reiterating full-year guidance. Investor focus now shifts to regulatory outcomes and the operational ramp for the flagship franchise transition.

Summary

• Ambutra Launch Readiness: Alnylam is intensifying commercial and medical preparation for the anticipated ATTR cardiomyopathy indication.
• CNS Pipeline Momentum: Positive multi-dose Alzheimer’s data and Huntington’s program progress expand the company’s non-liver RNAi reach.
• Disciplined Capital Deployment: Management is reallocating resources to high-impact programs, signaling operational focus amid pipeline expansion.

Business Overview

Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics for rare and prevalent diseases. The company’s business model centers on direct product sales from its four commercialized drugs across two main segments: the TTR franchise (Onpatro, Ambutra) for transthyretin-mediated amyloidosis, and the rare disease franchise (Givlaari, OXLUMO) for ultra-rare genetic disorders. Additional revenue comes from collaboration and royalty agreements, notably with partners like Novartis. Alnylam’s pipeline is anchored by proprietary RNAi technology, targeting genetic drivers of disease in the liver, CNS, and beyond.

Performance Analysis

Alnylam’s third quarter showcased strong execution in both commercial and pipeline domains. Total product revenue reached $420 million, up 34% year-over-year, with the TTR franchise contributing $309 million and rare disease products adding $111 million. The TTR franchise’s growth was driven by sustained patient uptake of Ambutra, particularly in the US where new patient adds and market share gains offset competitive pressures. International TTR sales dipped sequentially due to inventory and gross-to-net timing, yet underlying patient demand remained positive.

Rare disease products Givlaari and OXLUMO also posted double-digit growth, with regional strength in both the US and ex-US markets. Gross margin improved to 80%, reflecting normalization after prior-year manufacturing charges, though management expects a slight margin headwind next quarter due to higher royalties on Ambutra. Operating loss narrowed sharply as prior-year collaboration revenue lapped, and cash reserves increased to $2.8 billion, bolstered by operating performance and equity proceeds.

• TTR Franchise Scale: Nearly 5,000 patients are now on Onpatro or Ambutra globally, with a substantial addressable population (25,000–30,000) remaining.
• US Patient Uptake: Onpatro/Ambutra sales rose 8% sequentially and 37% YoY, demonstrating resilience despite new competition.
• Rare Disease Strength: Givlaari and OXLUMO delivered 34% and 40% YoY growth respectively, with robust international demand.

Revenue growth and margin expansion underscore the commercial engine’s strength, but the next phase of value creation hinges on the successful ATTR-CM launch and pipeline execution.

Executive Commentary

Strategic Positioning

1. ATTR-CM Launch as Pivotal Growth Lever

Alnylam is aggressively preparing for Ambutra’s potential label expansion in ATTR cardiomyopathy (ATTR-CM), which management describes as a transformative opportunity akin to blockbuster franchises in peer biotechs. With regulatory submissions complete in the US and EU, and priority review underway, the company has built commercial, medical, and market access infrastructure to support rapid uptake. The Helios-B study data, showing over 30% reduction in all-cause mortality, underpins a strong clinical value proposition for first-line positioning.

2. Pipeline Diversification Beyond Liver

Alnylam’s CNS pipeline is gaining traction, with positive multi-dose Alzheimer’s data (Mivelseran) and the advancement of Huntington’s disease candidate ALN-HTT02. Both programs leverage the company’s siRNA platform, with early evidence of robust, sustained target engagement and favorable tolerability. Management is also pursuing additional targets in muscle and adipose, aiming to double the clinical pipeline by 2025 and broaden the addressable market beyond hepatic diseases.

3. Resource Allocation and Portfolio Discipline

Alnylam is reallocating capital away from lower-priority assets, exemplified by the discontinuation of development for ALN-KHK in type 2 diabetes. This move reflects a focus on programs with the highest probability of technical and commercial success, particularly as the company nears sustainable profitability and faces the operational demands of a major launch.

4. Commercial Execution in Competitive Markets

The TTR franchise’s resilience amid new entrants demonstrates the strength of Alnylam’s quarterly dosing, patient support services, and rapid knockdown profile. The company’s US and international sales teams have maintained share and pricing discipline, even as payer and diagnostic complexity increases ahead of label expansion.

Key Considerations

This quarter marks a strategic inflection as Alnylam transitions from rare disease specialist to potential market leader in ATTR-CM, while expanding its pipeline into new organ systems. Execution risk is rising, but the company’s commercial and R&D infrastructure appears robust and battle-tested.

Key Considerations:

• Launch Complexity: The ATTR-CM opportunity requires education of cardiologists, payer negotiation, and rapid scale-up, all under regulatory uncertainty.
• Payer Dynamics: Management cites value-based agreements and minimal copay burden in polyneuropathy, but volume-based discounts and broader access hurdles may emerge with label expansion.
• Pipeline Breadth vs. Focus: Doubling the clinical pipeline by 2025 is ambitious; maintaining focus and capital discipline will be crucial as CNS and metabolic programs mature.
• Gross Margin Volatility: Royalty rates on Ambutra and inventory swings could pressure margins in the near term, despite recent improvement.

Risks

Regulatory approval for Ambutra in ATTR-CM is not guaranteed, and any delay or restrictive label could materially impact growth expectations. Competitive intensity is increasing in both TTR and rare disease markets, with new entrants and alternative modalities. Pipeline execution risk remains as Alnylam pushes into CNS and non-liver indications, where clinical and commercial pathways are less validated. Payer pushback and pricing pressure could also intensify as the patient population expands.

Forward Outlook

For Q4 2024, Alnylam guided to:

• Combined net product revenues of $1.575 to $1.65 billion for the full year
• Collaboration and royalty revenue of $575 million to $650 million
• Combined non-GAAP R&D and SG&A expenses of $1.775 to $1.875 billion

Management reaffirmed guidance, citing strong commercial trends and pipeline progress. Key upcoming milestones include additional ATTR amyloidosis data at AHA in November, a phase 3 plan for ALN-TTR-SCO4 in early 2025, and a phase 2 Alzheimer’s study initiation by year-end.

• ATTR-CM regulatory decisions expected in US and EU in early 2025
• Further CNS program updates and IND filings to double the pipeline by end of 2025

Takeaways

Alnylam’s Q3 results reinforce its position as a leader in RNAi therapeutics, with the TTR franchise delivering durable growth and the pipeline broadening into CNS and beyond. The upcoming ATTR-CM launch is set to define the company’s next phase, but execution and regulatory risk loom large.

• ATTR-CM Launch as Value Catalyst: Success in this indication could transform Alnylam’s revenue base and market profile, but launch execution and payer access will be critical watchpoints.
• CNS Pipeline Expansion: Early Alzheimer’s and Huntington’s data validate platform potential outside the liver, but clinical risk remains high in these indications.
• Focus on Capital Discipline: Management’s willingness to terminate lower-priority programs signals a commitment to sustainable growth amid pipeline expansion.

Conclusion

Alnylam exits Q3 2024 with momentum in both commercial and R&D fronts, setting the stage for a high-stakes ATTR-CM launch and further pipeline readouts. The company’s ability to execute on these fronts will determine whether it achieves durable, top-tier biotech status.

Industry Read-Through

Alnylam’s performance and strategic direction offer several read-throughs for the biotech sector. The success of RNAi in both rare and more prevalent indications signals growing investor confidence in gene-silencing modalities. The ATTR-CM launch preparation underscores the increasing importance of cross-specialty education and payer strategy as orphan drugs move into larger populations. The disciplined approach to portfolio management—trimming lower-priority assets to focus on high-yield programs—may become more common as biotechs face higher capital costs and demand for sustainable profitability. Finally, the expansion into CNS and extrahepatic targets highlights the ongoing race to unlock new therapeutic areas for RNA-based medicines, a trend likely to shape sector innovation and competition over the next several years.

ALNY Healthcare Biotechnology RNAi ATTR-CM CNS Pipeline Rare Disease